Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)
Hong Kong
· Delayed Price · Currency is HKD 24.00
-0.60 (-2.44%)
Apr 29, 2026, 4:08 PM HKT
Xuanzhu Biopharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 51.77 | 30.09 | 0.03 | - | - | Upgrade
|
| Revenue Growth (YoY) | 72.03% | 103672.41% | - | - | - | Upgrade
|
| Cost of Revenue | 18.4 | 14.94 | 2.19 | - | - | Upgrade
|
| Gross Profit | 33.37 | 15.16 | -2.17 | - | - | Upgrade
|
| Selling, General & Admin | 127.08 | 389.51 | 95.69 | 66.4 | 40.64 | Upgrade
|
| Research & Development | 124.19 | 186.4 | 239.06 | 350.17 | 197.71 | Upgrade
|
| Other Operating Expenses | - | 2.51 | 2.4 | 0.4 | 0.36 | Upgrade
|
| Operating Expenses | 251.27 | 578.42 | 337.14 | 416.96 | 238.69 | Upgrade
|
| Operating Income | -217.91 | -563.26 | -339.31 | -416.96 | -238.69 | Upgrade
|
| Interest Expense | -0.12 | -0.3 | -1.17 | -1.09 | -0.39 | Upgrade
|
| Interest & Investment Income | - | - | - | 31.39 | 8 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -0.01 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -27.47 | 14.77 | 40.03 | -0.1 | -0.06 | Upgrade
|
| EBT Excluding Unusual Items | -245.5 | -548.8 | -300.45 | -386.77 | -231.11 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.02 | -0.01 | 0.11 | 2.53 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -7.56 | - | -0.02 | 56.02 | Upgrade
|
| Asset Writedown | - | -0.05 | -0.1 | -92.25 | - | Upgrade
|
| Other Unusual Items | - | - | - | 17.36 | 10.12 | Upgrade
|
| Pretax Income | -245.5 | -556.42 | -300.56 | -461.58 | -162.45 | Upgrade
|
| Income Tax Expense | 0.01 | 0.01 | 0.01 | - | - | Upgrade
|
| Net Income | -245.51 | -556.43 | -300.56 | -461.58 | -162.45 | Upgrade
|
| Net Income to Common | -245.51 | -556.43 | -300.56 | -461.58 | -162.45 | Upgrade
|
| Shares Outstanding (Basic) | 465 | 451 | 451 | 395 | - | Upgrade
|
| Shares Outstanding (Diluted) | 465 | 451 | 451 | 395 | - | Upgrade
|
| Shares Change (YoY) | 3.15% | - | 14.22% | - | - | Upgrade
|
| EPS (Basic) | -0.53 | -1.23 | -0.67 | -1.17 | - | Upgrade
|
| EPS (Diluted) | -0.53 | -1.23 | -0.67 | -1.17 | - | Upgrade
|
| Free Cash Flow | - | -127.6 | -117.69 | -487.42 | -264.9 | Upgrade
|
| Free Cash Flow Per Share | - | -0.28 | -0.26 | -1.24 | - | Upgrade
|
| Gross Margin | 64.45% | 50.37% | - | - | - | Upgrade
|
| Operating Margin | -420.89% | -1871.67% | -1170020.69% | - | - | Upgrade
|
| Profit Margin | -474.21% | -1848.97% | -1036420.69% | - | - | Upgrade
|
| Free Cash Flow Margin | - | -424.00% | -405831.03% | - | - | Upgrade
|
| EBITDA | -190.37 | -535.73 | -315.26 | -398.82 | -223.22 | Upgrade
|
| D&A For EBITDA | 27.53 | 27.53 | 24.04 | 18.14 | 15.47 | Upgrade
|
| EBIT | -217.91 | -563.26 | -339.31 | -416.96 | -238.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.